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Whilst atrial ﬁbrillation (AF) is the commonest sustained
arrhythmia worldwide, it is also the arrhythmia of the elderly
with a lifetime AF risk >20% in the over 80s [1]. We are thus
on the brink of an AF pandemic, not only due to our ever-
agingpopulationbutalsoasaconsequenceofourpopulation
becoming increasingly obese and diabetic. In the US alone, it
is expected that the current AF prevalence of ∼5m i l l i o n
will at least double by the middle of the century [1]. This
represents a huge drain on healthcare resources, not only
from the direct management of the arrhythmia but from the
managementof the associated increased ratesof stroke, heart
failure, and dementia.
In the last decade, the care of AF has been revolutionised
[2] so that now we can realistically hope to cure some of our
AF patients through nonpharmacological therapies such as
catheter ablation or surgery. This issue examines the current
state of such therapies, points to their strengths, and their
weaknesses. One area where improvement is required is the
management of AF in the elderly; as eloquently reviewed by
L. M. Haegeli and F. Duru, the elderly are often diﬃcult to
treat medically because of their multiple comorbidities and
are often denied formal anticoagulation from which they
stand to gain the most beneﬁt. The elderly more often suc-
cumb to the proarrhythmic eﬀects of rhythm management
drugs and yet they are poorly represented in all the major
trials of catheter ablation.
Catheter ablation is fast becoming the ﬁrst line care for
paroxysmal AF. One exciting new way to administer this
therapy is through cryoablation. J. Ruskin et al. reviews how
this therapy is similarly as eﬀective as radiofrequency abla-
t i o nb u tw i t hl e s sp a i na n dp o s s i b l yw i t hl e s sa c u t et h r o m -
bogenicity. However, it is not as useful in persistent AF, but
what does work reliably in these patients is a contentious
issue as discussed in the article by K. P. Letsas et al. Here
the authors show that persistent AF cannot be treated by
PAVI (pulmonary antral vein isolation) alone but what is
the plus other remains contentious, especially as so many
of the extra manoeuvres increasing the risk of organised
atrial tachycardias as per S. Castrej´ on et al. Such tachycardias
are often more troublesome than the original AF, and the
ﬁnancial cost, as well as the emotional trauma, has to be
consideredwhenoneisweighingupthecostsofmanagement
by medication in comparison to management by nonphar-
macological care as nicely discussed by Y. Khaykin and Y.
Shamiss. Another potential cost saving step would be the
performance of catheter ablation without interruption of
anticoagulation as promoted by P. Santangeli et al.
In the last decade, the incorporation of alternative ad-
juncts to the traditional “cut and sew” has made the surgical
management of AF quicker and less technically demanding.
In this issue, we have three excellent reviews on the advance-
ments of surgical management. M. Castella et al. examine
the highly successful Cox-Maze III procedure and how it
has been developed with new adjuncts, whilst N. Hiari con-
centrates more on the pathophysiology of AF and how, like
catheter ablation, the new adjuncts in surgery are struggling
with how best to treat persistent AF. L. Harling et al.
discussed each of the adjuncts in turn before remonstrating2 Cardiology Research and Practice
how one of the major drawbacks in establishing their clinical
usefulness is the lack of homogeneity of (i) techniques used
and (ii) types of AF treated in the various trials. One area
of variation is the ligation of the left atrial appendage to
reduce the risk of thromboembolism. The ability to do this
procedure as an routine percutaneously procedure is coming
ever closer with advances in left atrial appendage occlusion
devices as reviewed by T. Contractor and A. Khasnis.
The paper by K. Mischke et al. reports on their basic
science research into rate control of AF by cooling. This
phenomenon is attractive in the management of new onset
AFinsepticpatientswithlowbloodpressureasthesepatients
are often resistant to cardioversion and all traditional agents
are negatively inotropic. Perhaps in the future, we will be
looking at active cooling as already instituted for post arrest
patients.
We hope you enjoy this issue that succinctly explores the
depth and breadth of currently available nonpharmacologi-
cal therapies for AF. Such therapies, which oﬀer the potential
tocure,willdoubtlessbecomemoreandmoreessentialaswe
attempt to cope with the Tsunami of AF that is approaching.
And so looking to the future, it is going to be both exciting
and challenging for interventional electrophysiologists of the
catheter and the blade.
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